Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 8
Submit an article Journal homepage
2,194
Views
16
CrossRef citations to date
0
Altmetric
Methods and Modelling

Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim

Ali McBrideArizona Cancer Center, Banner University Medical Center, Tucson, AZ, USA; ;College of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA; ;Department of Pharmacy Practice and Science College of Pharmacy, University of Arizona, Tucson, AZ, USA;
,
Weijia WangDepartment of Health Economics and Outcome Research, Sandoz Inc, Princeton, NJ, USA;
,
Kim CampbellDepartment of Health Economics and Outcome Research, Sandoz Inc, Princeton, NJ, USA;
,
Sanjeev BaluNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
,
Karen MacDonaldMATRIX45, Tucson, AZ, USA;
&
Ivo AbrahamCollege of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA; ;Department of Pharmacy Practice and Science College of Pharmacy, University of Arizona, Tucson, AZ, USA; ;MATRIX45, Tucson, AZ, USA; ;Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; ;Department of Family and Community Medicine College of Medicine – Tucson, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0490-4421
ORCID Icon
Pages 856-863 | Received 05 Feb 2020, Accepted 03 Apr 2020, Published online: 07 May 2020

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Hala H. Halawah, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mohammad Saleh, Shiraz S. Halloush, Omar Rashdan, Lama Masadh, Osama H. Abusara & Ivo Abraham. (2023) Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of Medical Economics 26:1, pages 835-842.
Read now
Consuela Cheriece Yousef, Mansoor Ahmed Khan, Hind Almodaimegh, Majed Alshamrani, Meteb Al-Foheidi, Hana AlAbdalkarim, Ahmed AlJedai, Anjum Naeem & Ivo Abraham. (2023) Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. Journal of Medical Economics 26:1, pages 394-402.
Read now
Nimer S Alkhatib, Shiraz Halloush & Ivo Abraham. (2023) The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region. Expert Opinion on Biological Therapy 23:8, pages 671-677.
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of Medical Economics 24:1, pages 743-756.
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Journal of Medical Economics 24:1, pages 598-606.
Read now
Karen MacDonald, Ali McBride, Neda Alrawashdh & Ivo Abraham. (2020) Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. Journal of Medical Economics 23:12, pages 1466-1476.
Read now

Articles from other publishers (10)

Sherin Ismail, Laila Abu Esba, Mansoor Khan, Hana Al-Abdulkarim, Hind Modimagh & Consuela Yousef. (2022) An Institutional Guide for Formulary Decisions of Biosimilars. Hospital Pharmacy 58:1, pages 38-48.
Crossref
Philip Q. Ding, Brandt J. Newcomer & Winson Y. Cheung. (2022) Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada. Cancers 14:24, pages 6197.
Crossref
Peter K. KaiserMarc Steffen Schmitz-Valckenberg & Frank G. Holz. (2022) ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY. Retina 42:12, pages 2243-2250.
Crossref
Sylvia A. van Laar, Kim B. Gombert-Handoko, Sophie Wassenaar, Judith R. Kroep, Henk-Jan Guchelaar & Juliette Zwaveling. (2022) Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients. Supportive Care in Cancer 30:11, pages 9181-9189.
Crossref
Paul Cornes, John Kelton, Rongzhe Liu, Omer Zaidi, Jennifer Stephens & Jingyan Yang. (2022) Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia. Future Oncology 18:16.
Crossref
Gina Wong, Katie Wang, Mark Pasetka, Liying Zhang, Julia Lou, Habeeb Majeed, Jerome Flores, Emily Lam & Carlo DeAngelis. (2022) The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study. Current Oncology 29:3, pages 1349-1369.
Crossref
Ali McBride, Neda Alrawashdh, Karen MacDonald & Ivo Abraham. (2022) Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncology 18:3, pages 363-373.
Crossref
Karen MacDonald, Neda Alrawashdh, Ali McBride & Ivo Abraham. (2021) Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology 17:33, pages 4561-4570.
Crossref
Ross M Maltz, Megan McNicol, Laura Wingate, Sarah Buchanan, Angela Sandell, Sandra C Kim & David T Rubin. (2021) There Is No Substitute for Effective Education About Biosimilars. Crohn's & Colitis 360 3:4.
Crossref
Ali McBride, Karen MacDonald & Ivo Abraham. (2021) Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. Leukemia Research 106, pages 106591.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.